September 5, 2025CancersOpen Access

Comparative Mechanistic Insights and Therapeutic Potential of Pembrolizumab, Durvalumab, and Ipilimumab as Immune Checkpoint Inhibitors in the Targeted Management of Oral and Head and Neck Squamous Cell Carcinoma

View Full Paper

Ask AI

Bookmark

Pembrolizumab significantly improves overall survival and progression-free survival in OSCC patients, enhancing treatment outcomes.
Durvalumab provides survival benefits in advanced cases, especially when used as a combination or maintenance therapy.
Ipilimumab shows durable responses in advanced OSCC, particularly effective in combination with nivolumab during dual blockade.
Immune checkpoint inhibitors require careful monitoring for immune-related adverse events, highlighting the importance of safety.

Discussion

No takes yet. Share an insight, caveat, or question.

Review reveals pembrolizumab, durvalumab, and ipilimumab improve survival in oral cancer, highlighting therapeutic potential.

Kawczak et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark